Parkinson's disease: An update on pathogenesis and treatment

Journal of Neurology

Volumn 260, Issue 5, 2013, Pages 1433-1440

  Foltynie, Tom ^a,b   Kahan, Joshua ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Parkinson's disease; Pathogenesis; Treatment; Update

Indexed keywords

DOPAMINE;

GENETICS; HUMAN; METABOLISM; PARKINSON DISEASE; PATHOLOGY; REVIEW;

DOPAMINE; HUMANS; PARKINSON DISEASE;

EID: 84891423973     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6915-1     Document Type: Article

References (76)

1. Hirsch EC, Jenner P, Przedborski S (2013) Pathogenesis of Parkinson's disease. Mov Disord 28(1):24-30.
2. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L (2011) Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10(11):1015-1025.
3. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P et al (2004) Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364(9440): 1169-1171.
4. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276(5321):2045-2047.
5. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: A meta-analysis of genome-wide association studies. Lancet 377(9766):641-649.
6. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D (2004) Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 305(5688):1292-1295.
7. Bezard E, Yue Z, Kirik D, Spillantini MG (2013) Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord 28(1):61-70.
8. Garcia-Reitbock P, Anichtchik O, Bellucci A, Iovino M, Ballini C, Fineberg E et al (2010) SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133(Pt 7):2032-2044.
9. Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T et al (2013) Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community- based incident cohort. Brain 136(Pt 2):392-399.
10. Duran R, Mencacci NE, Angeli AV, Shoai M, Deas E, Houlden H et al (2013) The glucocerebrosidase E326 K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Mov Disord 28(2):232-236.
11. Sidransky E, Lopez G (2012) The link between the GBA gene and Parkinsonism. Lancet Neurol 11(11):986-998.
12. Gegg ME, Burke D, Heales SJ, Cooper JM, Hardy J, Wood NW et al (2012) Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann Neurol 72(3):455-463.
13. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979-980.
14. Abramov AY, Gegg M, Grunewald A, Wood NW, Klein C, Schapira AH (2011) Bioenergetic consequences of PINK1 mutations in Parkinson disease. PLoS One 6(10):e25622.
15. Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI et al (2005) Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14(14):2063-2073.
16. Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogus H et al (2004) Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 19(5):544-548.
17. Bolam JP, Pissadaki EK (2012) Living on the edge with too many mouths to feed: why dopamine neurons die. Mov Disord 27(12): 1478-1483.
18. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML et al (2010) PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2(52):52-73.
19. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O et al (2011) PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 144(5):689-702.
20. Devi L, Anandatheerthavarada HK (2010) Mitochondrial trafficking of APP and alpha synuclein: relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases. Biochim Biophys Acta 1802(1):11-19.
21. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 486(3):235-239.
22. Arduino DM, Esteves AR, Cortes L, Silva DF, Patel B, Grazina M et al (2012) Mitochondrial metabolism in Parkinson's disease impairs quality control autophagy by hampering microtubuledependent traffic. Hum Mol Genet 21(21):4680-4702.
23. Cleeter MW, Chau KY, Gluck C, Mehta A, Hughes DA, Duchen M et al (2013) Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage. Neurochem Int 62(1):1-7.
24. Yap TL, Velayati A, Sidransky E, Lee JC (2013) Membranebound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol Genet Metab 108(1):56-64.
25. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24(2):197-211.
26. Li JY, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ et al (2008) Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14(5):501-503.
27. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A et al (2011) Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 72(1):57-71.
28. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ et al (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338(6109):949-953.
29. Alvarez-Erviti L, Seow Y, Schapira AH, Gardiner C, Sargent IL, Wood MJ et al (2011) Lysosomal dysfunction increases exosome- mediated alpha-synuclein release and transmission. Neurobiol Dis 42(3):360-367.
30. Cersosimo MG, Raina GB, Pecci C, Pellene A, Calandra CR, Gutierrez C et al. (2012) Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms. J Neurol.
31. Liu Z, Lee J, Krummey S, Lu W, Cai H, Lenardo MJ (2011) The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat Immunol 12(11):1063-1070.
32. Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Juzwiak S, Kurzawski G et al (2007) CARD15 variants in patients with sporadic Parkinson's disease. Neurosci Res 57(3):473-476.
33. Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) Use of ibuprofen and risk of Parkinson disease. Neurology 76(10): 863-869.
34. International Parkinson's disease Genetics Consortium (2011) A two-stage meta-analysis identifies several new loci for Parkinson's disease. PLoS Genet 7(6):e1002142.
35. Holmans P, Moskvina V, Jones L, Sharma M, Vedernikov A, Buchel F et al (2013) A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Hum Mol Genet 22(5):1039-1049.
36. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A et al (2006) In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21(2):404-412.
37. Lee JK, Tran T, Tansey MG (2009) Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 4(4):419-429.
38. Collins LM, Toulouse A, Connor TJ, Nolan YM (2012) Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease. Neuropharmacology 62(7):2154-2168.
39. Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S et al (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease. Neurosci Lett 270(1):45-48.
40. Mogi M, Togari A, Kondo T, Mizuno Y, Kogure O, Kuno S et al (2001) Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci Lett 300(3):179-181.
41. Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH (2010) Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res 184:237-264.
42. Gray R, Patel S, Ives N, Rick C, Jenkinson C, Wheatley K et al (2012) A large randomised trial assessing quality of life in patients with early PD: results from PD MED Early. Parkinsonism Relat Disord 18(Suppl 2):S33.
43. Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RM et al. (2013) Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: An evidencebased review. J Neurol.
44. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L et al (2013) Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 368(7):610-622.
45. Gervais-Bernard H, Xie-Brustolin J, Mertens P, Polo G, Klinger H, Adamec D et al (2009) Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol 256(2):225-233.
46. Park A, Stacy M (2012) Istradefylline for the treatment of Parkinson's disease. Expert Opin Pharmacother 13(1):111-114.
47. Hauser RA, Cantillon M, Pourcher E, Micheli F, Mok V, Onofrj M et al (2011) Preladenant in patients with Parkinson's disease and motor fluctuations: A phase 2, double-blind, randomised trial. Lancet Neurol 10(3):221-229.
48. Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M (2006) Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci 29(11):647-654.
49. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A et al (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26(7):1243-1250.
50. Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P et al (2013) Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol 20(2):271-280.
51. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351(24):2509-2518.
52. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R et al (2011) The movement disorder society evidence-based medicine review update: Treatments for the nonmotor symptoms of Parkinson's disease. Mov Disord 26(Suppl 3):S42-S80.
53. Shults CW, Flint BM, Song D, Fontaine D (2004) Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 188(2):491-494.
54. Parkinson's Disease Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Arch Neurol 59(12):1937-1943.
55. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
56. Foltynie T, Brayne C, Barker RA (2002) The heterogeneity of idiopathic Parkinson's disease. J Neurol 249(2):138-145.
57. Olanow CW, Kieburtz K, Schapira AH (2008) Why have we failed to achieve neuroprotection in Parkinson's disease Ann Neurol 64(Suppl 2):S101-S110.
58. Adhihetty PJ, Beal MF (2008) Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med 10(4):275-290.
59. NET-PD (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31(3):141-150.
60. Shen C, Guo Y, Luo W, Lin C, Ding M (2013) Serum urate and the risk of Parkinson's disease: results from a meta-analysis. Can J Neurol Sci 40(1):73-79.
61. Goldberg JA, Guzman JN, Estep CM, Ilijic E, Kondapalli J, Sanchez-Padilla J et al (2012) Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci 15(10):1414-1421.
62. Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C et al (2010) Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study. Mov Disord 25(16):2863-2866.
63. Dexter DT, Statton SA, Whitmore C, Freinbichler W, Weinberger P, Tipton KF et al (2011) Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm 118(2):223-231.
64. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC et al (2005) Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 25(28):6594-6600.
65. Aviles-Olmos I, Limousin P, Lees A, Foltynie T (2013) Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136(Pt 2):374-384.
66. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH (2002) Protection and reversal of excitotoxic neuronal damage by glucagon- like peptide-1 and exendin-4. J Pharmacol Exp Ther 302(3):881-888.
67. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW et al (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA 106(4): 1285-1290.
68. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflammation 5:19.
69. Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T et al. (2013) Exenatide and the treatment of Parkinson's disease. J Clin Invest, In press.
70. Lee Y, El AS, Wood MJ (2012) Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 21(R1):R125-R134.
71. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29(4):341-345.
72. Liu Z, Hamamichi S, Lee BD, Yang D, Ray A, Caldwell GA et al (2011) Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models. Hum Mol Genet 20(20):3933-3942.
73. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M et al (2003) Direct brain infusion of glial cell linederived neurotrophic factor in Parkinson disease. Nat Med 9(5):589-595.
74. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59(3):459-466.
75. Berry AL, Foltynie T (2011) Gene therapy: A viable therapeutic strategy for Parkinson's disease J Neurol 258(2):179-188.
76. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N et al (2010) Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol 9(12):1164-1172.